VERO (Venus Concept) Debt-to-Asset : 0.53 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Venus Concept Debt-to-Asset?

Venus Concept's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.00 Mil. Venus Concept's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $32.36 Mil. Venus Concept's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $72.28 Mil. Venus Concept's debt to asset for the quarter that ended in Sep. 2024 was 0.53.

Venus Concept Debt-to-Asset Historical Data

The historical data trend for Venus Concept's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Concept Debt-to-Asset Chart

Venus Concept Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.36

0.50

0.67

0.85

Venus Concept Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.85	0.85	0.95	0.63	0.53

Competitive Comparison of Venus Concept's Debt-to-Asset

For the Medical Devices subindustry, Venus Concept's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Concept's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Concept's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Venus Concept's Debt-to-Asset falls into.

Venus Concept Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Venus Concept's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.745	+	73.952)	/	93.654
	=	0.85

Venus Concept's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.996	+	32.358)	/	72.276
	=	0.53

Venus Concept (NAS:VERO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Venus Concept Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Venus Concept's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Concept Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Concept Inc (NAS:VERO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

235 Yorkland Boulevard, Suite 900, Toronto, ON, CAN, M2J 4Y8

Website

https://www.venusconcept.com

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

Executives

Anthony Natale	director	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Michael Willingham Masters	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Ross Portaro	officer: President Global Sales	235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Masters Special Situations, Llc	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Mss Vc Spv Lp	10 percent owner	C/O MASTERS SPECIAL SITUATIONS, LLC, 3060 PEACHTREE ROAD, NW, STE.1425, ATLANTA GA 30305
Marlin Fund Iii, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund Ii, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Capital Management Llc	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Silva Rajiv De	director, officer: Chief Executive Officer	1400 ATWATER DRIVE, MALVERN PA 19355
Marlin Master Fund Offshore Ii, Lp	10 percent owner	WAYSTONE CORP SV (CAYMAN) LTD, STE 5B201, FL 2, 1 NEXUS WAY, CAMANA BAY, BOX 1344, GRAND CAYMAN E9 KY1-1108
Hemanth Jacob Varghese	officer: President/Chief Bus. Officer	330 JOICEY BOULEVARD, TORONTO A6 M5M2W1
Stanley Tyler Hollmig	director	235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Penna Domenic Della	officer: Chief Financial Officer	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Anna Georgiadis	officer: VP, Global HR	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8